S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL

S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL

Bibliographic Details
Main Authors:	P. L. Zinzani, J. Mayer, R. Auer, F. Bijou, A. C. de Oliveira, C. R. Flowers, M. Merli, K. Bouabdallah, P. S. Ganly, Y. Song, H. Zhang, R. Johnson, A. M García-Sancho, M. Provencio, M. Trněný, S. Yuen, H. Tilly, E. Kingsley, G. Tuyman, S. E. Assouline, E. Ivanova, P. Kim, J. Huang, R. Delarue, J. Trotman
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000843712.33707.fe

Similar Items

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
by: Judith Trotman, et al.
Published: (2023-08-01)

Disseminated Enteroviral Infection Associated with Obinutuzumab
by: Claire Dendle, et al.
Published: (2015-09-01)

P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR FOLLOW-UP OF ELEVATE-TN
by: J. P. Sharman, et al.
Published: (2022-06-01)

Obinutuzumab in the treatment of PLA2R-positive membranous glomerulonephritis resistant to treatment
by: Francisco José de la Prada Álvarez, et al.
Published: (2024-03-01)

Impact of obinutuzumab alone and in combination for follicular lymphoma
by: Sarraf Yazdy M, et al.
Published: (2017-10-01)

Use of obinutuzumab for refractory autoimmune thrombocytopenia secondary to CLL
by: Rohitashva Agrawal, et al.
Published: (2020-07-01)

Research advances of obinutuzumab in the treatment of membranous nephropathy
by: Xiao-jing Lin, et al.
Published: (2024-01-01)

Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy
by: Supreet Sethi, et al.
Published: (2020-09-01)

The B cell death function of obinutuzumab-HDEL produced in plant (Nicotiana benthamiana L.) is equivalent to obinutuzumab produced in CHO cells.
by: Jin Won Lee, et al.
Published: (2018-01-01)

Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
by: Paul J. Hengeveld, et al.
Published: (2025-01-01)

Successful Use of Intravenous Immunoglobulins in an Obinutuzumab-related Acute Thrombocytopenia
by: Tobias R. Haage, et al.
Published: (2022-08-01)

Correction: The B cell death function of obinutuzumab-HDEL produced in plant (Nicotiana benthamiana L.) is equivalent to obinutuzumab produced in CHO cells.
by: Jin Won Lee, et al.
Published: (2018-01-01)

Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia
by: Sharad Khurana, et al.
Published: (2019-01-01)

The Occurrence of Richter’s Syndrome during Treatment with Obinutuzumab and Chlorambucil
by: Teng Fong Ng, et al.
Published: (2020-01-01)

Obinutuzumab in Refractory Membranous Nephropathy: A Case Series
by: Yuxin Lin, et al.
Published: (2024-08-01)

Clinical application of obinutuzumab for treating chronic lymphocytic leukemia
by: Luan C, et al.
Published: (2019-08-01)

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
by: Al-Sawaf O, et al.
Published: (2017-01-01)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
by: Othman Al-Sawaf, et al.
Published: (2023-04-01)

Combining Obinutuzumab With Radiation for Refractory DLBCL: Retrospective Safety and Efficacy Analysis
by: Brett A. Morris, MD, PhD, et al.
Published: (2024-07-01)

Obinutuzumab in membranous nephropathy: a potential game-changer in treatment
by: Concetto Sessa, et al.
Published: (2025-02-01)

Obinutuzumab for the Treatment of Cold Agglutinin Disease: A Case Report
by: Siyuan Li, et al.
Published: (2024-09-01)

New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab
by: Shah A
Published: (2015-07-01)

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
by: Smolej L
Published: (2014-12-01)

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
by: Othman Al-Sawaf, et al.
Published: (2023-10-01)

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL-102)
by: M. Hamadani, et al.
Published: (2022-06-01)

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
by: Michael Herold, et al.
Published: (2022-03-01)

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
by: Carol Moreno, et al.
Published: (2022-01-01)

Obinutuzumab-Induced Inflammatory Bowel Disease-Like Pancolitis: A First Case Report
by: Raquel R. Mendes, et al.
Published: (2023-09-01)

Obinutuzumab en el tratamiento de la glomerulonefritis membranosa PLA2R positiva resistente a tratamiento
by: Francisco José de la Prada Álvarez, et al.
Published: (2024-03-01)

Obinutuzumab-induced acute thrombocytopenia: a case report and literature review
by: Xuelin Dou, et al.
Published: (2024-12-01)

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
by: Andrew Grigg, et al.
Published: (2017-04-01)

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
by: Natali Pflug, et al.
Published: (2021-12-01)

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL
by: Annamaria Mascolo, et al.
Published: (2023-08-01)

Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus
by: Johanna Freund, MD, et al.
Published: (2022-09-01)

Coxsackievirus A16 Encephalitis during Obinutuzumab Therapy, Belgium, 2013
by: Tom Eyckmans, et al.
Published: (2014-05-01)

P674: UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
by: C. Ryan, et al.
Published: (2022-06-01)

P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY
by: S. Opat, et al.
Published: (2022-06-01)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
by: Nadine Kutsch, et al.
Published: (2022-06-01)

Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
by: Christopher R. Flowers, et al.
Published: (2023-09-01)

P1103: OBINUTUZUMAB INDUCTION AND MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINAEMIA
by: Tomasz Wróbel, et al.
Published: (2023-08-01)